1060811-62-2

Usage

Uses

Due to the limited information available about 4,6-dichloronicotinaldehyde, it is difficult to provide a comprehensive list of its applications. However, based on its classification as a dialkylpyridine and a derivative of nicotinaldehyde, it can be inferred that it may have potential uses in various industries, such as:
Used in Chemical Synthesis Industry:
4,6-Dichloronicotinaldehyde may be used as an intermediate or building block in the synthesis of more complex organic compounds, given its structural features and the presence of chlorine atoms that can be further functionalized.
Used in Pharmaceutical Industry:
As a derivative of nicotinaldehyde, 4,6-dichloronicotinaldehyde could potentially be used in the development of new pharmaceutical compounds, particularly if its chemical properties allow for the formation of novel molecular structures with therapeutic potential.
Used in Research and Development:
4,6-Dichloronicotinaldehyde may be utilized in academic or industrial research settings to study its chemical properties, reactivity, and potential applications in various fields, such as materials science, catalysis, or environmental chemistry.

Upstream product

• 65973-52-6 methyl 4,6-dichloropyridine-3-carboxylate 
• 73998-95-5 2,4-dichloro-5-hydroxymethylpyridine 
• 40296-46-6 ethyl 4,6-dichloronicotinate 
• 1830-54-2 3-oxopentanedioic acid dimethyl ester 
• 79398-27-9 methyl 4,6-dihydroxypyridine-3-carboxylate 
• 6975-44-6 4,6-dihydroxynicotinic acid ethyl ester 
• 105-50-0 diethyl 1,3-acetonedicarboxylate 
• 73027-79-9 4,6-dichloro-nicotinic acid 

Downstream Products

• 1558302-68-3 6-chloro-1-methyl-1H-pyrazolo[4,3-c]pyridine 
• 449811-29-4 6-chloro-4-(methylamino)pyridine-3-carbaldehyde 

Relevant academic research and scientific papers

A Facile Synthesis of New 4,6-Dichloropyridine Derivatives, Their Biological Evaluation for Antimicrobial and Antioxidant Activity, and Docking Studies

A facile synthesis of new 4,6-dichloropyridine derivatives 5(a–f), 6(a–c), and 7(a–c) were synthesized using both conventional heating and solvent-free microwave irradiation techniques. The results revealed that the latter method is superior to the conventional heating method. The easy work-up of the products, rapid reaction, and mild conditions are noticeable features of this protocol. Structural elucidation of the synthesized compounds was made on the basis of various spectroscopic methods. The synthesized compounds were evaluated for their in vitro antimicrobial activity (minimum inhibitory concentration; MIC) against various microbial strains using the agar well-diffusion method. Among the compounds, 5c showed best antimicrobial activity against most of the employed strains, especially against Staphylococcus aureus, Escherichia coli, Rhizopus arrhizus, and Candida albicans. Compounds 5a, 6a, 6c, 7a, and 7c showed significant antioxidant activity when compared to the other compounds. In addition to this, theoretical docking studies were performed for the highly potent compounds 5a, 6a, 6c, 7a, and 7c against three different drug targets belonging to the oxidoreductase family, and the results were found to be highly satisfactory.

Synthesis and antibacterial evaluation of hydrazone derivatives bearing 6-chlorothieno[3,2-c]pyridine Moiety

The present investigation describes the overall preparation of 6-chlorothieno[3,2-c]pyridine-2-carbohydrazide-hydrazone subsidiaries (7a-r) from industrially accessible ethyl-4,6-dichloronicotinate as starting material. The synthesis of these derivatives

TRICYCLIC KINASE INHIBITORS AND USE THEREOF

The present application provides novel compounds that are inhibitors of kinases, including AMPK-related kinases like NUAK1, NUAK2, SIK1, SIK2, SIK3, MARK1, MARK2, MARK3, MARK4, as well as AURKA, AURKB, AURKC, CLK1, CLK2, DCAMKL2, MAPK7, MKNK2, PIK3CD, PKN3, RET, TAOK1, TAOK2, TAOK3, ULK2 and their mutants. The application also provides compositions, including pharmaceutical compositions, kits that include compounds, and methods of making and using compounds. The compounds provided herein are useful in treating diseases, disorders, or conditions that are mediated by these kinases.

3,4-dihydropyrido[4,3-d]pyrimidine derivative, and preparation method and use thereof

The invention relates to a 3,4-dihydropyrido[4,3-d]pyrimidine derivative, and a preparation method and a use thereof. The compound is a compound represented by formula I, or a pharmaceutically acceptable salt or stereoisomer or tautomer thereof, and R to R are as defined in the description.

CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME

The present disclosure relates to solid forms of N-{[2'-(2,6-difluoro-3,5-dimethoxyphenyl)-3'-oxo-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-[2,7]naphthyridin]-6'-yl]methyl}acrylamide, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the FGFR-associated or mediated diseases such as cancer.

TYK2 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

N-(2-(4-((1R,3R)-3-METHYL-2,3,4,9-TETRAHYDRO-1H-PYRIDO[3,4-B]INDOL-1-YL)PHENOXY)ETHYL)PROPAN-1-AMINE DERIVATIVES AND RELATED COMPOUNDS AS SELECTIVE DOWN-REGULATORS OF THE ESTROGEN RECEPTOR FOR TREATING CANCER

The specification relates to compounds of Formula (I) and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, pharmaceutical compositions containing them and to the compounds of Formula (I) for use as selective down-regulators of the estrogen receptor in the treatment of cell proliferative disorders, such as cancer.

BICYCLIC PROLINE COMPOUNDS

The invention is concerned with the compounds of formula (I) and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Fibroblast growth factor receptor selective inhibitor and application thereof

The invention relates to a fibroblast growth factor receptor selective inhibitor and application thereof. The invention provides a compound of a formula (I), a three-dimensional isomer, a tautomer or a pharmaceutically acceptable salt thereof, and an appl

Fibroblast growth factor receptor selective inhibitor and applications thereof

The invention discloses a fibroblast growth factor receptor selective inhibitor and applications thereof. The invention provides a compound as shown in a formula (I), and a stereoisomer, a tautomer or pharmaceutically accepted salts thereof, and applicati